Clark Estates Inc. NY Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Clark Estates Inc. NY bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 62,000 shares of the biopharmaceutical company's stock, valued at approximately $2,964,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Heck Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $69,000. Farther Finance Advisors LLC raised its stake in Halozyme Therapeutics by 173.6% during the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,028 shares during the period. Finally, Parkside Financial Bank & Trust raised its stake in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 1.4 %

Shares of Halozyme Therapeutics stock traded up $0.83 on Friday, reaching $60.98. The company had a trading volume of 1,491,680 shares, compared to its average volume of 1,306,249. The firm's 50 day moving average price is $55.70 and its two-hundred day moving average price is $54.77. The firm has a market cap of $7.51 billion, a PE ratio of 17.78, a PEG ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark reaffirmed a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday. Finally, Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.